Evidence map›Paper›PMID 31673238›Full record

ArticleInternational journal of medical sciences2019

Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts.

Víctor J Costela-Ruiz, Lucia Melguizo-Rodríguez, Rebeca Illescas-Montes, Javier Ramos-Torrecillas, Francisco J Manzano-Moreno, Concepción Ruiz, Elvira De Luna- Bertos

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Repercussions of Bisphenol A on the Physiology of Human Osteoblasts.International journal of molecular sciences · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Víctor J Costela-RuizBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Lucia Melguizo-RodríguezBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Rebeca Illescas-MontesBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Javier Ramos-TorrecillasBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Francisco J Manzano-MorenoInstituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain.
Concepción RuizBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Elvira De Luna- BertosBiomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
Universidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the treatment of choice but are the least studied with respect to their repercussion on bone. The objective of this study was to determine the effects of celecoxib on cultured human osteoblasts. Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5μM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). Therapeutic doses of celecoxib had no effect on osteoblast cell growth or antigen expression but had a negative impact on the gene expression of RUNX2 and OSC, although there was no significant change in the expression of ALP and OSX. Celecoxib at therapeutic doses has no apparent adverse effects on cultured human osteoblasts and only inhibits the expression of some differentiation markers. These characteristics may place this drug in a preferential position among NSAIDs used for analgesic and anti-inflammatory therapy during bone tissue repair.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCelecoxibCell DifferentiationCell ProliferationCell SurvivalCore Binding Factor Alpha 1 SubunitCyclooxygenase 2Flow CytometryGene Expression Regulation, DevelopmentalHumansOsteoblastsOsteocalcinOsteogenesisPrimary Cell CultureSp7 Transcription FactorAnti-Inflammatory Agents, Non-SteroidalCelecoxibCore Binding Factor Alpha 1 SubunitCyclooxygenase 2OsteocalcinRUNX2 protein, humanSP7 protein, humanSp7 Transcription Factorbone.celecoxibCOX-2 selective NSAIDsosteoblast differentiationosteoblasts

Identifiers

PMID31673238
PMCPMC6818209
OpenAlexW2976938963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.